BEY2153
- Generic Name
- BEY2153
A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease
Phase 2
Not yet recruiting
- Conditions
- Alzheimer DiseaseAlzheimer' Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06885567
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
🇰🇷Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- BeyondBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT04476303
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath